APOBEC signature mutation generates an oncogenic enhancer that drives LMO1 expression in T-ALL-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

APOBEC signature mutation generates an oncogenic enhancer that drives LMO1 expression in T-ALL

Published:2017-03-06 Issue:10 Volume:31 Page:2057-2064
ISSN:0887-6924
Container-title:Leukemia
language:en
Short-container-title:Leukemia

Author:

Li Z,Abraham B J,Berezovskaya A,Farah N,Liu Y,Leon T,Fielding A,Tan S H,Sanda T,Weintraub A S,Li B,Shen S,Zhang J,Mansour M R,Young R A,Look A T

Publisher

Springer Science and Business Media LLC

Subject

Oncology,Cancer Research,Hematology

Link

http://www.nature.com/articles/leu201775.pdf

Reference42 articles.

1. Wheeler DA, Wang L . From human genome to cancer genome: the first decade. Genome Res 2013; 23: 1054–1062.

2. Khurana E, Fu Y, Chakravarty D, Demichelis F, Rubin MA, Gerstein M . Role of non-coding sequence variants in cancer. Nat Rev Genet 2016; 17: 93–108.

3. Horn S, Figl A, Rachakonda PS, Fischer C, Sucker A, Gast A et al. TERT promoter mutations in familial and sporadic melanoma. Science 2013; 339: 959–961.

4. Huang FW, Hodis E, Xu MJ, Kryukov GV, Chin L, Garraway LA . Highly recurrent TERT promoter mutations in human melanoma. Science 2013; 339: 957–959.

5. Mansour MR, Abraham BJ, Anders L, Berezovskaya A, Gutierrez A, Durbin AD et al. Oncogene regulation. An oncogenic super-enhancer formed through somatic mutation of a noncoding intergenic element. Science 2014; 346: 1373–1377.

Cited by 59 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Precision Genome Editing Techniques in Gene Therapy: Current State and Future Prospects;Current Gene Therapy;2024-10

2. Oncogenic Enhancers in Leukemia;Blood Cancer Discovery;2024-08-01

3. Developmental origins shape the paediatric cancer genome;Nature Reviews Cancer;2024-05-02

4. HemaCisDB: An Interactive Database for Analyzing Cis-Regulatory Elements Across Hematopoietic Malignancies;2024-03-13

5. Myb overexpression synergizes with the loss of Pten and is a dependency factor and therapeutic target in T‐cell lymphoblastic leukemia;HemaSphere;2024-03

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3